CareDx (NASDAQ:CDNA) Share Price Crosses Below Two Hundred Day Moving Average - Time to Sell?

Key Points

• CareDx shares fell below its 200-day moving average (200‑day MA $17.47), trading as low as $17.20 and last at $17.84 on heavy volume — a potential bearish technical signal.
• The company posted a quarterly EPS miss ($0.12 reported vs. $0.24 expected) despite revenue beating estimates at $108.39M and rising 25% year‑over‑year; analysts hold a consensus "Hold" rating with an average target of $27.33.
• Insiders have been selling (CEO sold 19,280 shares; 29,636 shares sold in the past 90 days, insiders own 4.4%), while institutional investors like Goldman Sachs have increased positions, reflecting mixed insider and institutional activity.

CareDx, Inc. (NASDAQ:CDNA - Get Free Report) passed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $17.47 and traded as low as $17.20. CareDx shares last traded at $17.84, with a volume of 641,998 shares.

Wall Street Analysts Forecast Growth

CDNA has been the topic of several recent analyst reports. Craig Hallum downgraded shares of CareDx from a "buy" rating to a "hold" rating and set a $26.00 target price on the stock. in a research note on Tuesday, January 6th. Wall Street Zen downgraded CareDx from a "buy" rating to a "hold" rating in a report on Saturday, February 7th. BTIG Research lifted their price target on CareDx from $25.00 to $26.00 and gave the company a "buy" rating in a report on Wednesday, February 25th. Weiss Ratings lowered CareDx from a "hold (c-)" rating to a "sell (d)" rating in a research report on Friday, February 27th. Finally, Wells Fargo & Company increased their price objective on CareDx from $18.00 to $21.00 and gave the stock an "equal weight" rating in a research note on Wednesday, February 25th. Three research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, CareDx presently has a consensus rating of "Hold" and an average target price of $27.33.

CareDx Price Performance

The firm has a market capitalization of $913.76 million, a PE ratio of -44.60 and a beta of 2.52. The company has a fifty day moving average of $19.13 and a 200-day moving average of $17.47.

CareDx (NASDAQ:CDNA - Get Free Report) last issued its earnings results on Tuesday, February 24th. The company reported $0.12 EPS for the quarter, missing analysts' consensus estimates of $0.24 by ($0.12). The firm had revenue of $108.39 million during the quarter, compared to analysts' expectations of $102.76 million. CareDx had a negative net margin of 5.65% and a negative return on equity of 6.50%. The business's revenue for the quarter was up 25.2% compared to the same quarter last year. During the same quarter last year, the firm earned $0.18 EPS. Equities analysts anticipate that CareDx, Inc. will post -0.9 EPS for the current year.

Insiders Place Their Bets

In other CareDx news, CEO John Walter Hanna, Jr. sold 19,280 shares of CareDx stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $21.16, for a total value of $407,964.80. Following the completion of the sale, the chief executive officer directly owned 597,405 shares in the company, valued at $12,641,089.80. The trade was a 3.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold a total of 29,636 shares of company stock worth $625,949 over the last 90 days. 4.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Goldman Sachs Group Inc. increased its holdings in shares of CareDx by 18.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,110,014 shares of the company's stock valued at $19,703,000 after acquiring an additional 170,504 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of CareDx by 11.3% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 133,966 shares of the company's stock valued at $2,378,000 after acquiring an additional 13,619 shares in the last quarter. Envestnet Asset Management Inc. lifted its holdings in CareDx by 17.7% in the 2nd quarter. Envestnet Asset Management Inc. now owns 22,489 shares of the company's stock worth $439,000 after purchasing an additional 3,389 shares during the last quarter. PNC Financial Services Group Inc. lifted its holdings in CareDx by 162.0% in the 2nd quarter. PNC Financial Services Group Inc. now owns 11,702 shares of the company's stock worth $229,000 after purchasing an additional 7,236 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in CareDx by 3.4% during the second quarter. Geode Capital Management LLC now owns 1,323,497 shares of the company's stock worth $25,864,000 after purchasing an additional 43,074 shares during the period.

CareDx Company Profile

CareDx, Inc NASDAQ: CDNA is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company's core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.